Search hospitals > Maryland > Hanover
Chesapeake Urology Research Associates
Claim this profileHanover, Maryland 21076
Global Leader in Bladder Cancer
Conducts research for Vulval Intraepithelial Neoplasia
Conducts research for Urinary Tract Infection
Conducts research for Stress Incontinence
Conducts research for Transitional Cell Carcinoma
21 reported clinical trials
1 medical researcher
Summary
Chesapeake Urology Research Associates is a medical facility located in Hanover, Maryland. This center is recognized for care of Bladder Cancer, Vulval Intraepithelial Neoplasia, Urinary Tract Infection, Stress Incontinence, Transitional Cell Carcinoma and other specialties. Chesapeake Urology Research Associates is involved with conducting 21 clinical trials across 28 conditions. There are 1 research doctors associated with this hospital, such as Rian Dickstein, MD.Area of expertise
1Bladder Cancer
Global LeaderFGFR positive
Stage II
Stage I
2Vulval Intraepithelial Neoplasia
Top PIs
Clinical Trials running at Chesapeake Urology Research Associates
Bladder Cancer
Transitional Cell Carcinoma
Hematuria
Vulval Intraepithelial Neoplasia
Nadofaragene Firadenovec
for Bladder Cancer
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).
Recruiting2 awards Phase 33 criteria
TAR-210
for Bladder Cancer
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Recruiting2 awards Phase 34 criteria
Cxbladder Triage Plus
for Hematuria
This study includes adult patients who see a urologist because of blood in their urine. The amount is so small it can only be seen with a microscope. This is called microhematuria. There can be many reasons for microhematuria. One of them is bladder cancer. While bladder cancer is one of the biggest worries, it is only found in few of these patients. Most microhematuria patients will have a cystoscopy to look inside the bladder. During a cystoscopy, a small camera is inserted into the bladder. This is done through the urethra, the tube that passes urine from the bladder to the outside. In some patients it can cause pain or anxiety. Not all patients have a cystoscopy. Those that don't, usually return for a urine sample within 6 months. This is done to check if there is still blood in their urine. This study is conducted to find out if the use of "Cxbladder Triage Plus" changes the number of cystoscopies in microhematuria patients. Cxbladder Triage Plus is also called "Triage Plus". It is a lab test that was developed to check how likely urothelial carcinoma is present in the bladder. Urothelial carcinoma is by far the most common type of bladder cancer. For the test, the patient voids some urine into a cup. A laboratory then checks the urine of specific genetic material. Abnormalities can be a sign of urothelial carcinoma. The result indicates if the urine is more like most normal urine or more like that of urothelial carcinoma patients. The study is done to find out how Triage Plus changes the number of cystoscopies. Study participants first void urine into a cup. The urine is used for the Triage Plus test. The patients are then assigned to one of two groups. The assignment is random. This means the nobody can influence the assignment. The chance to be assigned to either group is the same. In the test group, the urologist will receive the Triage Plus result and discuss it with the patient. Together they decide whether to do a cystoscopy. In the control group, the urologist will not receive the Triage Plus result. The patient will also not get the result. The urologist and patient will follow standard of care to decide whether to do a cystoscopy. For test group patients, the study gives a recommendation whether to proceed with cystoscopy. It is based on the patient's Triage Plus result. The urologist and patient do not need to follow the recommendation. If the urologist does not follow it, they will complete a survey. The survey has only one question. It is asking for the reasons of the decision. After making their decision, patients will follow the chosen pathway. Data on the performed procedures are collected. The diagnosis will also be documented. Data will be collected for up to about 9 months. To see how Triage Plus changes the number of cystoscopies, these will be counted in each group and then compared.
Recruiting1 award N/A2 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Chesapeake Urology Research Associates?
Chesapeake Urology Research Associates is a medical facility located in Hanover, Maryland. This center is recognized for care of Bladder Cancer, Vulval Intraepithelial Neoplasia, Urinary Tract Infection, Stress Incontinence, Transitional Cell Carcinoma and other specialties. Chesapeake Urology Research Associates is involved with conducting 21 clinical trials across 28 conditions. There are 1 research doctors associated with this hospital, such as Rian Dickstein, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.